By Rick Valachovic, DMD, MPH, Clinical Professor and Director of the NYU Dentistry Center for Oral Health Policy and Management

If you could protect your children from most oral cancers with a vaccine, would you make sure they got it? You just might — if you knew the vaccine existed and understood how deadly these cancers can be.

I’m talking, of course, about the human papilloma virus (HPV), which is thought to cause 70% of oropharyngeal cancers (OPCs). Although these cancers of the tongue and throat are relatively rare, their prognosis is bleak. They kill an estimated 40% of OPC patients within five years and can be extraordinarily painful. The good news is that many of these cancers are preventable if people are vaccinated against HPV before they are exposed to the cancer-causing pathogen.

“I counsel my patients starting at age nine, and I ask, ‘Has your pediatrician spoken to you about the HPV vaccine?’” says Lauren Feldman, DMD, MPH, clinical assistant professor at NYU Dentistry and pediatric dentistry postdoctoral program director. She informs families that HPV is the leading cause of OPCs and tells them, “As your dental health professional, I recommend that you’re vaccinated to prevent against this.”

When I was practicing pediatric dentistry earlier in my career, this vaccine was not at our disposal. Had it been, I would have eagerly recommended it. Research shows that anticipatory guidance from a trusted health professional is an effective tool for encouraging vaccination, even among parents who have initially declined it for their children.

The HPV Vaccine: Effective but Underutilized

In 2006, the Food and Drug Administration approved the first HPV vaccine. It was developed to prevent cervical cancer and originally offered to girls and young women. Less than two decades later, research shows just how effective the vaccine has been. One study found cervical HPV infection was significantly less prevalent in the first generation of U.S. women aged 18 to 32 who received the vaccine than in their counterparts born 10 years earlier (5.6% vs. 12.5%). A separate study found an 87% reduction in cervical cancer rates among the first generation of girls aged 12-13 in England who received the vaccine.

Not surprisingly, vaccination has affected the rates of oral cancer as well. The Centers for Disease Control and Prevention (CDC) reported that women accounted for 3,617 HPV-related OPCs from 2015 to 2019 while finding 17,000—more than 4.5 times as many—cases among men. “We’re seeing a decrease in women because of vaccination,” Lauren told me. “This is a public health win.”

The CDC now recommends the HPV vaccine for 11- to 12-year-olds of both sexes and for everyone through the age of 26 who has not already been immunized. HPV vaccination rates are inching up, but they are considerably lower than the immunization rates for some other common childhood diseases. In 2021, the CDC estimated that only 62% of 13- to 17-year-olds had received all recommended doses of the HPV vaccine. In contrast, the rates of immunization against tetanus, diphtheria, chickenpox, the measles, and several other diseases met or exceeded 90%. Since the likelihood of HPV exposure increases as adolescents age, the CDC website now states the vaccine may be given as early as age 9.

What Dental Professionals Can Do

What can dental professionals and dental schools do to increase HPV vaccine uptake? Lauren believes we can be most effective by starting conversations. “We should be asking our patients, ‘Did you get your first dose? When’s your next dose scheduled?’” she argues. “We need to reinforce the need to go back and to finish the course.”

I hope today’s dentists will follow her advice, but many will encounter parents whose skepticism about the value of the HPV vaccine may have been exacerbated during the COVID-19 pandemic. When the HPV vaccine first became available, the media focused on parental fears that vaccination might encourage children to become sexually active. Research suggests this was (and remains) a minority view. Nevertheless, a quarter of parents believe the vaccine is unnecessary, and almost as many parents refused the vaccine in 2018 over concerns about safety. This finding is especially troubling because only 13% of parents listed safety as a concern in 2015, and reported adverse events associated with its administration fell dramatically over the same time period. Given documented links between vaccine refusal rates and exposure to misinformation via social media, the researchers speculate that misinformation may be responsible for the rise in safety concerns.

Despite the availability of patient education resources on the American Academy of Pediatrics website, many parents clearly remain unaware of the vaccine’s value and its availability. Judging from what Lauren has heard in her private practice, few pediatricians offer patients the vaccine before age 12. She’s also heard anecdotally that some don’t recommend HPV vaccination to their male patients despite offering it to girls in their care.

Can these barriers be overcome? Lauren believes they can.

“The HPV vaccine is unique because it’s cancer prevention,” she reasons. “If somebody is hesitant to get one vaccine, I wouldn’t assume that means that they’re hesitant against all vaccines.” As she points out, most immunocompetent people will recover from influenza, and the flu vaccine has a much lower rate of efficacy than the HPV vaccine does. In contrast, “cancer’s ‘big C’ scary,” she says.

I hope people take HPV-caused cancer as seriously as Lauren does and see the vaccine for the lifeline that it is. In the meantime, dental professionals can use their influence to inform patients about the vaccine’s benefits and the cancers it prevents. We owe it to our patients to talk about HPV.